Manchester Capital Management LLC Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Manchester Capital Management LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,280 shares of the company’s stock after selling 1,222 shares during the quarter. Manchester Capital Management LLC’s holdings in Johnson & Johnson were worth $3,141,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Zions Bancorporation N.A. increased its position in shares of Johnson & Johnson by 0.4% during the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after acquiring an additional 73 shares during the period. Portland Global Advisors LLC increased its position in shares of Johnson & Johnson by 0.9% during the third quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after acquiring an additional 78 shares during the period. SRS Capital Advisors Inc. increased its position in shares of Johnson & Johnson by 0.5% during the third quarter. SRS Capital Advisors Inc. now owns 17,452 shares of the company’s stock worth $2,258,000 after acquiring an additional 79 shares during the period. Vishria Bird Financial Group LLC increased its position in shares of Johnson & Johnson by 3.0% during the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after acquiring an additional 80 shares during the period. Finally, Alta Capital Management LLC increased its position in shares of Johnson & Johnson by 3.9% during the third quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock worth $282,000 after acquiring an additional 82 shares during the period. 72.22% of the stock is currently owned by hedge funds and other institutional investors.

NYSE JNJ traded up $0.02 during trading hours on Wednesday, hitting $131.37. The company had a trading volume of 1,990,628 shares, compared to its average volume of 7,202,121. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company has a market cap of $350.04 billion, a PE ratio of 16.06, a price-to-earnings-growth ratio of 2.25 and a beta of 0.69. The business has a 50 day moving average of $130.88 and a 200-day moving average of $133.96.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. During the same quarter in the prior year, the firm posted $2.05 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 annualized dividend and a yield of 2.89%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

A number of research firms have recently weighed in on JNJ. Raymond James cut their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What are CEFs?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Phoenixcoin Price Reaches $0.0023 on Major Exchanges
Phoenixcoin Price Reaches $0.0023 on Major Exchanges
DAIICHI SANKYO/S  Now Covered by Jefferies Financial Group
DAIICHI SANKYO/S Now Covered by Jefferies Financial Group
Zscaler  Given “Buy” Rating at Credit Suisse Group
Zscaler Given “Buy” Rating at Credit Suisse Group
Baozun  Coverage Initiated by Analysts at HSBC
Baozun Coverage Initiated by Analysts at HSBC
Pentair  Stock Rating Reaffirmed by Cowen
Pentair Stock Rating Reaffirmed by Cowen
STRATA Skin Sciences  Coverage Initiated at LADENBURG THALM/SH SH
STRATA Skin Sciences Coverage Initiated at LADENBURG THALM/SH SH


© 2006-2019 Ticker Report